Medicare copays for new Alzheimer's drug could reach $11,500
A new $56,000-a-year Alzheimer’s drug would raise Medicare premiums broadly, and some patients who are prescribed the medication could face copayments of about $11,500 annually, according to a research report published Wednesday.
BIAS DISTRIBUTION
Medicare copays for new Alzheimer's drug could reach $11,500
A new $56,000-a-year Alzheimer’s drug would raise Medicare premiums broadly, and some patients who are prescribed the medication could face copayments of about $11,500 annually, according to a research report published Wednesday. The drug, called Aduhelm, was approved by the Food and Drug Administration only this week. It's the first Alzheimer's medication in nearly 20 years, though it doesn't cure the life-sapping neurological condition.
Medicare copays for new Alzheimer's drug could reach $11,500
A new report says the $56,000 Alzheimer’s drug approved this week would raise Medicare premiums broadly
Medicare copays for new Alzheimer's drug could reach $11,500
WASHINGTON (AP) — A new $56,000-a-year Alzheimer’s drug would raise Medicare premiums broadly, and some patients who are prescribed the medication could face copayments of about $11,500 annually, according to a research report published Thursday.
Medicare Copays For New Alzheimer's Drug Could Reach $11,500 Annually
Some advisors to the Food and Drug Administration have quit over the drug which critics say has questionable benefits. The FDA said it can reduce clumps of plaque in the brain and may slow dementia.(Image credit: Biogen via AP)
Medicare copays for new Alzheimer's drug could reach $11,500
"At this price, the cost of this one drug alone could top all others covered by Medicare, if it is used widely."
Medicare copays for new Alzheimer’s drug could reach $11,500
By RICARDO ALONSO-ZALDIVAR and MATTHEW PERRONEWASHINGTON (AP) — A new $56,000-a-year Alzheimer’s drug would raise Medicare premiums broadly, and some patients who are prescribed the medication could face copayments of about $11,500 annually, according to a research report published Thursday.The drug, called Aduhelm, was approved by the Food and Drug Administration this week and quickly sparked controversy over its price-tag and questionable bene…
Medicare copays for new Alzheimer's drug could reach $11,500
A new $56,000-a-year Alzheimer's drug would raise Medicare premiums broadly, and some patients who are prescribed the medication could face copayments of about $11,500 annually, according to a research report published Thursday.
Medicare copays for new Alzheimer’s drug could reach $11,500
By Ricardo Alonso-Zaldivar and Matthew Perrone | Associated PressWASHINGTON — A new $56,000-a-year Alzheimer’s drug would raise Medicare premiums broadly, and some patients who are prescribed the medication could face copayments of about $11,500 annually, according to a research report published Thursday.The drug, called Aduhelm, was approved by the Food and Drug Administration this week and quickly sparked controversy over its price-tag and que…
Medicare copays for new Alzheimer’s drug could reach $11,500
WASHINGTON (AP) — A new $56,000-a-year Alzheimer’s drug would raise Medicare premiums broadly, and some patients who are prescribed the medication could face copayments of about $11,500 annually, according to a research report published Thursday.The drug, called Aduhelm, was approved by the Food and Drug Administration this week and quickly sparked controversy over its price-tag and questionable benefits.It’s the first Alzheimer’s medication in …
Medicare copays for new Alzheimer's drug could reach $11,500
A new $56,000-a-year Alzheimer’s drug would raise Medicare premiums broadly, and some patients who are prescribed the medication could face copayments of about $11,500 annually, according to a research report published Wednesday.The drug, called Aduhelm, was approved by the Food and Drug Administration only this week. It's the first Alzheimer's medication in nearly 20 years, though it doesn't cure the life-sapping neurological condition. Some e…
BIAS DISTRIBUTION
